38.09 
0.14(0.37%) May 24, 4:00PM EDT
| Prev Close: | 38.23 |
|---|
| Open: | 37.82 |
|---|
| Bid: | 37.87 x 400 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 40.91 |
|---|
| Beta: | 1.09 |
|---|
| Next Earnings Date: | 15-Jul-13 |
|---|
| Day's Range: | 37.48 - 38.45 |
|---|
| 52wk Range: | 28.12 - 46.00 |
|---|
| Volume: | 206,553 |
|---|
| Avg Vol (3m): | 392,119 |
|---|
| Market Cap: | 2.56B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Primecap Rides Health to Top Growth Fund: Riskless Returnat Bloomberg(Wed, May 15)
- Neutral Rating Restated for CepheidZacks(Mon, May 13)
- CEPHEID FinancialsEDGAR Online Financials(Fri, May 10)
- Cepheid Welcomes Executive Vice President of Global OperationsPR Newswire(Tue, May 7)
- CEPHEID Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, FiEDGAR Online(Tue, May 7)
- DexCom Loss Narrower than Est.Zacks(Thu, May 2)
- CEPHEID Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Thu, May 2)
- CEPHEID Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 2)
- Cepheid to Webcast Upcoming Financial PresentationsPR Newswire(Wed, May 1)
- ResMed's Earnings Beat; Revs LagZacks(Mon, Apr 29)
- FDA Taking More Aggressive Approach in Areas of Totally Unmet Medical Need, Granting Breakthrough Status to New Drugs in Development if No Other Therapeutic OptionWall Street Transcript(Fri, Apr 26)
- Target Executive Officer Sells More Than 41K Shares and 4 Insider Sales to Noteat Wall St. Cheat Sheet(Wed, Apr 24)
- Did These Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sun, Apr 21)
- Covidien Expands Shiley OfferingsZacks(Fri, Apr 19)
- FDA Nod for Luminex OfferingZacks(Fri, Apr 19)
Key Statistics
| Forward P/E (1 yr): | 158.71 |
|---|
| P/S (ttm): | 7.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.00 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market.
View More